The year 2024 saw major advancements in alopecia research, with key highlights including the FDA approval of the oral Janus kinase inhibitor Leqselvi for severe alopecia areata in adults. Other significant articles focused on the use of oral contraceptive pills in frontal fibrosing alopecia, prescribers favoring oral minoxidil for androgenetic alopecia, and the association of low-dose metformin with improvement in central centrifugal cicatricial alopecia. Additionally, continual hair regrowth up to 68 weeks was observed in patients with alopecia treated with deuruxolitinib. Various studies and trials also explored the efficacy of different treatments for alopecia, such as topical finasteride, minoxidil combinations, and the phase 1 trial of ET-02 for androgenic alopecia treatment.
Source link
Leqselvi approval tops Healio’s most-read alopecia news in 2024
